VACC News and Press, Vaccitech plc From 06/22/22

Vaccitech (NASDAQ:VACC) plans to offer 2.16M shares represented by ADS offered by selling stockholders. The ADSs being offered were issued to the selling shareholders as part of the company acquisition of Avidea Technologies in December 2021. The company will receive no proceeds from sale of ...

VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient transaminitis. Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) wer...

The following slide deck was published by Vaccitech plc in conjunction with this event. For further details see: Vaccitech (VACC) Investor Presentation - Slideshow

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enrig...

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its e...

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enrigh...

Vaccitech press release (NASDAQ:VACC): Q1 GAAP EPS of $0.07. Revenue of $15M. Shares -0.6%. For further details see: Vaccitech GAAP EPS of $0.07, revenue of $15M

OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceut...

Vaccitech (NASDAQ:VACC) said it had been notified that it would receive $15M as its share of milestone and royalty payments from AstraZeneca’s sales of Vaxzevria vaccine during the fourth quarter of 2021. U.K. biopharma Vaccitech and Oxford University co-created the COVID-19 vacci...

OXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that it has been notified of the commencement of royalty pay...